Accelerated proliferation of solid
tumor and hematologic
cancer cells is linked to accelerated transcription of
rDNA by the
RNA polymerase I (Pol I)
enzyme to produce elevated levels of rRNA (rRNA). Indeed, upregulation of Pol I, frequently caused by mutational alterations among
tumor suppressors and oncogenes, is required for maintenance of the
cancer phenotype and forms the basis for seeking selective inhibitors of Pol I as anticancer
therapeutics. 2-(4-Methyl-[1,4]diazepan-1-yl)-5-oxo-5H-7-thia-1,11b-diaza-
benzo[c]fluorene-6-
carboxylic acid (5-methyl-pyrazin-2-ylmethyl)-amide (CX-5461, 7c) has been identified as the first potent, selective, and orally bioavailable inhibitor of
RNA Pol I transcription with in vivo activity in
tumor growth efficacy models. The preclinical data support the development of
CX-5461 as an anticancer
drug with potential for activity in several types of
cancer.